All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tricaprylin
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
Tricaprilin, is an investigational oral drug version of a medium chain triglyceride, which has been designed to induce ketosis and thereby improve mitochondrial metabolism.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Golimumab
Therapeutic Area: Neurology Product Name: ION373
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
ION373 is an Ionis-owned investigational antisense medicine designed to stop the mutated gene from producing excess GFAP. Earlier this year, the European Medicines Agency (EMA) granted orphan drug designation to ION373.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): M102
Therapeutic Area: Neurology Product Name: M102
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: FightMND
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Funding September 29, 2020
Details:
The grant will support the translational development of M102, a drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PBFT02
Therapeutic Area: Neurology Product Name: PBFT02
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
In the study, a single administration of an optimized adeno-associated virus containing the GRN gene resulted in elevated levels of progranulin in the brain and cerebral spinal fluid, normalized lysosomal enzyme expression and corrected microgliosis in a mouse models.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Levodopa
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
LiberaTx, an NTU-incubated start-up is now commercialising new slow-release pill that delivers L-dopa over a period of 24 hours, which could help to alleviate symptoms related to Parkinson’s disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RNA editing therapies
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Wu Capital
Deal Size: $91.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 10, 2020
Details:
This financing enables Korro to advance its lead program to IND filing and establish a broad portfolio of innovative RNA editing therapies. Korro’s OPERA platform, harnesses the body’s natural base editing system, specifically ADAR to make targeted edits to a single RNA base.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): 4-Chlorokynurenine,Probenecid
Therapeutic Area: Neurology Product Name: AV-101
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
The results of this new study complement previous preclinical data demonstrating the combination's potential to substantially increase the brain concentration of AV-101's active metabolite, 7-Cl-KYN, thereby reducing, rather than blocking, NMDA receptor signaling.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ebselen
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2020
Details:
The team have developed a number of ebselen-based compounds with improvements in SOD1 stabilisation and in vitro therapeutic effects with significantly better potency than edaravone.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AL002
Therapeutic Area: Neurology Product Name: AL002
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
5XFAD mice in the intracranial administration study were assigned to one of two injection groups: AL002a, a Trem2-agonizing antibody, or MOPC, an isotype-matched control antibody.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KLS-13019
Therapeutic Area: Neurology Product Name: KLS-13019
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
With the PCT Patent, along with Kannalife’s novel lead drug candidate, KLS-13019, and its other novel therapeutic agents like Atopidine™, Kannalife now has near global coverage in the top pharmaceutical markets in the world.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
